AstraZeneca Secures NMPA Approval for Fasenra in EGPA, Demonstrating Superior Steroid-Sparing Effect
AstraZeneca PLC (AZ, NASDAQ: AZN) announced that Fasenra (benralizumab) has received additional approval from China’s...
Innovent Biologics Secures NMPA Approval for TABOSUN as First Neoadjuvant Dual‑IO Therapy for MSI‑H/dMMR Colon Cancer
Innovent Biologics, Inc. (HKG: 1801) announced that China’s National Medical Products Administration (NMPA) has approved...
Wantai Biological Secures NMPA Approval for First Oral HIV Self-Test Kit in China
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392) announced that its Human Immunodeficiency Virus...
Allist Pharmaceuticals Secures Breakthrough Therapy Designation for Furmonertinib in EGFR PACC‑Mutated NSCLC
Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that furmonertinib has been added to the Breakthrough...
UniPath Bronchoscopic Robot Wins NMPA Approval, Expanding MedBot’s Surgical Portfolio
Shanghai MicroPort MedBot (Group) Co., Ltd. (HKG: 2252) announced that its self‑developed UniPath Electronic Bronchoscopic...
Livzon’s Lecankitug Accepted by NMPA as First Domestic Dual IL‑17A/F Psoriasis Drug
Livzon Pharmaceutical Group Inc. (HKG: 1513) announced that China’s National Medical Products Administration (NMPA) accepted...
Novo Nordisk’s Sogroya Wins NMPA Approval for Pediatric Growth Hormone Deficiency
Novo Nordisk (NYSE: NVO) announced that its once‑weekly long‑acting growth hormone (LAGH) injection, Sogroya (somapacitan), received...
J&J’s Amivantamab Subcutaneous Wins China Approval for NSCLC
Johnson & Johnson (J&J, NYSE: JNJ) announced that its Amivantamab Injection (Subcutaneous), marketed as RYBREVANT, received...
Hybio Pharmaceutical, Dr. Reddy’s Forge Peptide API Partnership
Hybio Pharmaceutical and Dr. Reddy’s Laboratories entered a strategic partnership, signing a non‑binding Term Sheet...
NDRC Expands Foreign Investment in Healthcare with 2025 Catalogue
The National Development and Reform Commission (NDRC) issued the “Catalogue of Industries Encouraging Foreign Investment...
NMPA Issues Internet Pharma Info Rules Requiring Record-Filing Display
China’s National Medical Products Administration (NMPA) released the “Announcement on the Provisions for the Administration...
Shionogi Acquires RADICAVA ALS Business for $2.5 Billion from Tanabe Pharma
Shionogi & Co., Ltd. (Japan) announced it will acquire 100% of the shares of a...
Novo Nordisk’s Wegovy Wins China Cardiovascular Approval in Weight-Loss Market Expansion
Novo Nordisk (NYSE: NVO) announced that China’s National Medical Products Administration (NMPA) approved Wegovy (semaglutide)...
Aosaikang’s Delafloxacin Wins NMPA Approval as First Fluoroquinolone for China Infections
Beijing Aosaikang Pharmaceutical Co., Ltd. (SHE: 002755) announced that China’s National Medical Products Administration (NMPA)...
Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal
Coherent Biopharma announced an exclusive licensing agreement with MultiValent Biotherapies, Inc. for CBP‑1018, a bispecific...
3SBio’s rhTPO Wins NMPA Approval for Liver Disease Thrombocytopenia Before Surgery
3SBio Inc. (HKG: 1530) announced that its Recombinant Human Thrombopoietin (rhTPO) injection received National Medical...
Gilead’s Seladelpar Wins China Hainan Approval for PBC Treatment
Gilead Sciences (NASDAQ: GILD) announced that Seladelpar (marketed as Livdelzi), a potent and selective PPARδ...
Alphamab JSKN003 ADC FDA Breakthrough Therapy Targets Ovarian Cancer
Alphamab Oncology (HKG: 9966) announced that its independently developed HER2‑targeting biparatopic antibody‑drug conjugate (ADC), JSKN003,...
CDE Reference Standards 101st Batch Seeks Public Feedback
China’s Center for Drug Evaluation (CDE) announced it is seeking public feedback on the 101st...
Jemincare JMX-2005 PAD Injection Secures NMPA Clinical Trial Approval
Jiangxi Jemincare Group (SHA: 603222) announced that its Class 2.2 and Class 2.4 new drug application for...